Skip to main content
CagriSema is a once-weekly injection that combines two appetite-reducing hormone copies in one pen: semaglutide, which acts like the gut hormone GLP-1, and cagrilintide, which acts like amylin, a hormone released by the pancreas after eating. It has finished large phase 3 studies, but no medicines regulator anywhere has approved it.
CagriSema has no marketing authorisation anywhere in the world. Novo Nordisk filed an application with the United States regulator on 18 December 2025, and no marketing authorisation has been granted in the European Union. No doctor in the EU — including Hi-Doctor’s — can legally prescribe it, and no EU pharmacy can dispense it. Anything sold online under this name is not a licensed medicine.

​
Can I get it?

Not yet, and not from anyone in the EU. CagriSema is still being studied; it has no marketing authorisation, so it cannot legally be prescribed or dispensed here outside a clinical trial. That is the law, not a limitation of any one clinic.

​
What can I take instead?

Semaglutide is approved in the EU, has published peer-reviewed trial results, and can be prescribed today if a doctor decides it suits a case. It has been authorised in the EU since 6 January 2022.

Semaglutide (Wegovy / Ozempic)

Weekly GLP-1 receptor agonist. A doctor may prescribe it if BMI and history match the indications. Requires follow-up.

Tirzepatide (Mounjaro)

Dual GLP-1/GIP agonist. Assessed by the doctor based on comorbidities and BMI.

Liraglutide (Saxenda)

Daily GLP-1 agonist. Indicated in selected patients with elevated BMI after medical evaluation.

Orlistat 120mg

Fat-absorption inhibitor. A non-GLP-1 alternative a doctor may consider based on history.

Rybelsus (oral semaglutide)

A once-daily semaglutide tablet authorised for type 2 diabetes. Any use in weight management is an individual medical decision and may be off-label.

​
How CagriSema works

It copies GLP-1, a hormone the gut releases after a meal, which reduces appetite and slows how quickly the stomach empties, alongside a copy of amylin acting on calcitonin/amylin receptors.

​
What the studies reported

Every trial behind CagriSema is listed here with its registry number and whether the results are peer-reviewed or a company announcement. Results are grouped by source and evidence grade so journal data and manufacturer announcements cannot be confused.
Published in the New England Journal of Medicine. ClinicalTrials.gov record: NCT05567796.
Published in the New England Journal of Medicine. ClinicalTrials.gov record: NCT05394519.
Novo Nordisk filed for FDA approval of CagriSema on 18 December 2025. No corresponding EU filing has resulted in a marketing authorisation.
Every NCT identifier links to its ClinicalTrials.gov record. A trial readout is not the same as a peer-reviewed publication.

​
A note on comparing to semaglutide

Semaglutide’s own weight-loss evidence, from its STEP 1 trial, measured mean change with the 2.4 mg once-weekly dose at 68 weeks; the placebo arm’s mean change was −2.4%. This is a separate trial from CagriSema’s REDEFINE studies, not a direct comparison — results for CagriSema may come from a different dose, duration and patient group.

​
How Hi-Doctor handles it

The product is the online doctor consultation. A licensed doctor decides case by case, and treatment — and a prescription — follow only if the doctor approves. Renewals are reviewed by the same doctor, with ongoing care available for as long as a plan is active. Medication, if prescribed, is paid separately at the pharmacy — Hi-Doctor does not sell medications. See pricing for what the consultation covers.

​
Start a consultation

Weight-loss consultation

Answer the weight-loss questionnaire and a registered doctor reviews it. They decide whether treatment is appropriate, which one, and at what dose — and declining is a normal outcome. See what it costs and how the review works.
This page is reference information, not medical advice and not a prescription. Whether a medicine is appropriate for you is decided by a registered doctor after reviewing your consultation.